Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Trial designs used to study neuroprotective therapy in Parkinson's disease.

Lang AE, Melamed E, Poewe W, Rascol O.

Mov Disord. 2013 Jan;28(1):86-95. doi: 10.1002/mds.24997. Epub 2012 Aug 23. Review.

PMID:
22927060
2.

Designing neuroprotection trials in Parkinson's disease.

Kieburtz K.

Ann Neurol. 2003;53 Suppl 3:S100-7; discussion S107-9. Review.

PMID:
12666102
3.

Concerning neuroprotective therapy for Parkinson's disease.

Uitti RJ, Wszolek ZK.

J Neural Transm Suppl. 2006;(70):433-7. Review.

PMID:
17017564
4.

Issues in neuroprotection clinical trials in Parkinson's disease.

Kieburtz K.

Neurology. 2006 May 23;66(10 Suppl 4):S50-7.

PMID:
16717252
5.

Neuroprotection in Parkinson's disease: an elusive goal.

Biglan KM, Ravina B.

Semin Neurol. 2007 Apr;27(2):106-12. Review.

PMID:
17390255
6.

Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?

Hung AY, Schwarzschild MA.

Curr Opin Neurol. 2007 Aug;20(4):477-83. Review.

PMID:
17620885
7.

Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings.

Marras C, Lang AE.

Expert Rev Neurother. 2004 Nov;4(6):985-93. Review.

PMID:
15853525
8.

Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.

Löhle M, Reichmann H.

J Neurol Sci. 2010 Feb 15;289(1-2):104-14. doi: 10.1016/j.jns.2009.08.025. Epub 2009 Sep 20. Review.

PMID:
19772974
9.
10.

Clinical trials aimed at detecting neuroprotection in Parkinson's disease.

Hauser RA, Zesiewicz TA.

Neurology. 2006 May 23;66(10 Suppl 4):S58-68.

PMID:
16717253
11.

Neuroprotection in Parkinson's disease: clinical trials.

Stocchi F, Olanow CW.

Ann Neurol. 2003;53 Suppl 3:S87-97; discussion S97-9. Review.

PMID:
12666101
12.

Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?

Clarke CE.

Mov Disord. 2008 Apr 30;23(6):784-9. doi: 10.1002/mds.21918.

PMID:
18175348
13.

A responsive outcome for Parkinson's disease neuroprotection futility studies.

Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GF, Tanner CM, Palesch YY, Huang P, Guimaraes P, Kamp C, Tilley BC, Kieburtz K; NET-PD Investigators.

Ann Neurol. 2005 Feb;57(2):197-203.

PMID:
15668964
14.

Neurobiology and treatment of Parkinson's disease.

Schapira AH.

Trends Pharmacol Sci. 2009 Jan;30(1):41-7. doi: 10.1016/j.tips.2008.10.005. Epub 2008 Nov 29. Review.

PMID:
19042040
15.

Obstacles to the development of a neuroprotective therapy for Parkinson's disease.

Stocchi F, Olanow CW.

Mov Disord. 2013 Jan;28(1):3-7. doi: 10.1002/mds.25337. Review.

PMID:
23390094
16.

Why have we failed to achieve neuroprotection in Parkinson's disease?

Olanow CW, Kieburtz K, Schapira AH.

Ann Neurol. 2008 Dec;64 Suppl 2:S101-10. doi: 10.1002/ana.21461. Review.

PMID:
19127580
17.

The use of rasagiline in Parkinson's disease.

Schapira AH.

J Neural Transm Suppl. 2006;(71):157-61. Review.

PMID:
17447426
18.

A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's disease.

McGhee DJ, Ritchie CW, Zajicek JP, Counsell CE.

BMC Neurol. 2016 Jun 16;16:92. doi: 10.1186/s12883-016-0606-3. Review.

19.

Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment.

Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, Marler JR.

Neurology. 2003 Apr 22;60(8):1234-40. Review.

PMID:
12707423
20.

Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.

Meissner W, Hill MP, Tison F, Gross CE, Bezard E.

Trends Pharmacol Sci. 2004 May;25(5):249-53. Review.

PMID:
15120490

Supplemental Content

Support Center